205 related articles for article (PubMed ID: 35962510)
1. Bullous pemphigoid in India: Review of cases registered in an autoimmune bullous disease clinic.
De D; Kaushik A; Handa S; Mahajan R; Chatterjee D; Saikia B; Saikia UN; Radotra BD; Minz RW
Indian J Dermatol Venereol Leprol; 2023; 89(4):553-557. PubMed ID: 35962510
[TBL] [Abstract][Full Text] [Related]
2. Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin.
Goyal N; Rao R; Shenoi SD; Pai S; Kumar P; Bhogal BS; Schmidt E; Zillikens D
Indian J Dermatol Venereol Leprol; 2017; 83(5):550-555. PubMed ID: 28749386
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases.
García-Díez I; Martínez-Escala ME; Ishii N; Hashimoto T; Mascaró Galy JM; Pujol RM; Herrero-González JE
Actas Dermosifiliogr; 2017; 108(1):e1-e5. PubMed ID: 27095685
[TBL] [Abstract][Full Text] [Related]
4. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
[TBL] [Abstract][Full Text] [Related]
5. Clinical, demographic and immunopathological spectrum of subepidermal autoimmune bullous diseases at a tertiary center: A 1-year audit.
De D; Khullar G; Handa S; Saikia UN; Radotra BD; Saikia B; Minz RW
Indian J Dermatol Venereol Leprol; 2016; 82(3):358. PubMed ID: 27088957
[TBL] [Abstract][Full Text] [Related]
6. Anti-P 200 pemphigoid - The most common floor binding subepidermal autoimmune bullous disease in a tertiary care center in south India.
Rai R; Anand JB; Shanmugasekar C; Arunprasath P; Chaitra V; Zillikens D; Schimdt E
Indian J Dermatol Venereol Leprol; 2021; 87(6):787-791. PubMed ID: 34160166
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing Epidermolysis Bullosa Acquisita From Bullous Pemphigoid Without Direct Immunofluorescence.
Gardner KM; Crawford RI
J Cutan Med Surg; 2018; 22(1):22-24. PubMed ID: 28719980
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid.
Korman N
J Am Acad Dermatol; 1987 May; 16(5 Pt 1):907-24. PubMed ID: 3294944
[TBL] [Abstract][Full Text] [Related]
10. Bullous autoimmune dermatoses.
Hofmann SC; Juratli HA; Eming R
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
[TBL] [Abstract][Full Text] [Related]
11. Utility of Direct Immunofluorescence Studies in Subclassification of Autoimmune Sub-Epidermal Bullous Diseases: A 2-Year Study in a Tertiary Care Hospital.
Jain S; Basavaraj V; Vimala MG
Turk Patoloji Derg; 2016; 32(2):91-8. PubMed ID: 27136107
[TBL] [Abstract][Full Text] [Related]
12. A subepidermal blistering disease with histopathological features of dermatitis herpetiformis and immunofluorescence characteristics of bullous pemphigoid: a novel subepidermal blistering disease or a variant of bullous pemphigoid?
Salmhofer W; Kawahara Y; Soyer HP; Kerl H; Nishikawa T; Hashimoto T
Br J Dermatol; 1997 Oct; 137(4):599-604. PubMed ID: 9390339
[TBL] [Abstract][Full Text] [Related]
13. Survival and prognostic factors in bullous pemphigoid: A retrospective cohort study.
Papara C; Chiorean R; Leucuta DC; Baican C; Danescu S; Sitaru C; Zillikens D; Baican A
Indian J Dermatol Venereol Leprol; 2023; 89(3):363-371. PubMed ID: 36331841
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
15. Annular bullous diseases.
Sussman M; Zhai L; Morquette A; Huang S; Hsu S
Clin Dermatol; 2022; 40(5):516-528. PubMed ID: 34979265
[TBL] [Abstract][Full Text] [Related]
16. [Bullous pemphigoid, a dermatosis of the elderly].
Hébert V; Joly P
Rev Prat; 2017 Dec; 67(10):1080-1083. PubMed ID: 30512605
[TBL] [Abstract][Full Text] [Related]
17. Direct immunofluorescence microscopy of 1 mol/L sodium chloride-treated patient skin.
Domloge-Hultsch N; Bisalbutra P; Gammon WR; Yancey KB
J Am Acad Dermatol; 1991 Jun; 24(6 Pt 1):946-51. PubMed ID: 1869682
[TBL] [Abstract][Full Text] [Related]
18. [Autoimmune bullous skin disorders].
Hertl M; Niedermeier A; Borradori L
Ther Umsch; 2010 Sep; 67(9):465-82. PubMed ID: 20806175
[TBL] [Abstract][Full Text] [Related]
19. Association of bullous pemphigoid and comorbid health conditions: a case-control study.
Lee S; Rastogi S; Hsu DY; Nardone B; Silverberg JI
Arch Dermatol Res; 2021 Jul; 313(5):327-332. PubMed ID: 32647978
[TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
